Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Oxiracetam and Unifiram — mechanism, side effects, legal status, and pricing.
Oxiracetam is a non-peptide racetam-class cognitive enhancer, structurally the 4-hydroxy analog of piracetam. It is approved as a prescription drug for dementia in Italy (since 1984) and China, but is NOT FDA-approved in the United States. The FDA has classified oxiracetam as a 'new drug' requiring approval and determined it does not qualify as a dietary supplement; in the US it is sold only as an unregulated gray-market research chemical.
Unifiram (DM-232) is a synthetic non-peptide small-molecule nootropic structurally related to sunifiram, though not a racetam itself. It originated from Italian academic research (University of Florence) in the early 2000s and has never progressed beyond preclinical animal studies; it is not an approved or investigational drug in any regulatory database. Unifiram is sold openly by research-chemical vendors as an unregulated laboratory reagent. No human data of any kind exist.
Oxiracetam
Unifiram
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Oxiracetam
No pricing data yet.
Check Oxiracetam prices →Unifiram
COA corpus from Disclosed Labs — independently tested batches only.
Oxiracetam
2
COAs
99.4%
Avg purity
2
Labs
Unifiram
1
COAs
99.4%
Avg purity
1
Labs
Multiple placebo-controlled human trials exist in dementia, organic brain syndrome, and traumatic brain injury populations, plus human pharmacokinetic studies. One double-blind controlled trial in elderly organic-brain-syndrome patients used doses titrated from 400–2400 mg/day; a separate placebo-controlled trial in senile dementia of Alzheimer type and multi-infarct dementia used 800 mg twice daily and reported improvement on cognitive measures versus placebo. Preclinical findings include AMPA receptor modulation and enhanced neurotransmitter release in rat hippocampal preparations, and identification of the (S)-enantiomer as the active component alleviating cognitive impairment in a rat chronic cerebral hypoperfusion model. Oral bioavailability in humans is ~56% (versus 28–42% in rats, 81–90% in dogs), with predominantly renal excretion of unchanged drug.
Key references
No human data of any kind exist for unifiram; no registered clinical trials or published human studies were found. All available evidence is from rodent behavioral and in-vitro electrophysiology studies. In mice and rats, unifiram (0.001–1 mg/kg i.p. or 0.01–0.1 mg/kg oral) reversed amnesia induced by scopolamine, mecamylamine, baclofen, clonidine, and NBQX in passive-avoidance and Morris water-maze tests, at doses roughly 1,000-fold lower than piracetam, without impairing motor coordination or altering spontaneous locomotor activity. No systematic toxicology (repeat-dose, genotoxicity, carcinogenicity) studies have been published.
Oxiracetam and Unifiram are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs